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We compared survival and death-censored technique
survival in patients on automated peritoneal dialysis
(automated dialysis) or on continuous ambulatory peritoneal
dialysis. All 4128 patients from the Australia and New
Zealand Dialysis and Transplant Registry who started
peritoneal dialysis over a 5-year period through March 2004
were included. Times to death and death-censored technique
failure were analyzed by Cox proportional hazards models
while a conditional risk set model computed technique
failure. Compared to patients treated entirely with
continuous ambulatory peritoneal dialysis, automated
peritoneal dialysis patients were more likely to be young,
Caucasian, have marginally lower body mass index, and were
less likely to have baseline cardiovascular disease or diabetes.
Using univariate and multivariate analysis, our study showed
there were no significant differences in patient survival and
death-censored technique failure between the two types of
peritoneal dialysis modalities.
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Much research has been undertaken over the last 20 years to
improve the quality of treatment provided by peritoneal dialysis
(PD). One of the most promising advances has been the
introduction of automated PD (APD). The use of cyclers in
North America has increased from 10% in 1990 to 54% in
2000.1 In Australia, APD usage has increased from 4% in 1995 to
42% in 2004.2 Globally, it has been estimated that approximately
one-third of PD patients are being maintained on APD.3
Several studies have reported a number of significant
advantages of APD over continuous ambulatory PD (CAPD),
including reduced peritonitis rates,4–9 enhanced ultrafiltra-
tion,10–12 improved quality of life,13–15 augmented small
solute clearances,16,17 decreased mechanical complications
(hernias, leaks, back pain), and body image difficulties.13,18
However, these benefits have not been confirmed by other
investigators.19–24 Moreover, some authors have observed that
APD may be associated with deleterious consequences, such
as greater cost21,25 and accelerated loss of residual renal
function.22,26,27 Evaluations of the impact of PD modality on
survival outcomes are similarly limited and contradictory. A
study of North American PD patients tracked by a Baxter
Healthcare database reported significantly improved overall
survival and technique success rates in patients treated with
APD compared to those treated with CAPD.28 In contrast, a
pediatric registry report and several smaller studies have
found no differences in outcomes between APD and CAPD
populations.9,21,29 However, many of these investigations
have suffered from a number of potentially important
limitations, including ascertainment bias, recall bias, center
effects, vintage bias, selection bias, and absent or inadequate
statistical adjustment for differences in baseline character-
istics between APD and CAPD populations.
The aim of this study was to compare patient survival and
death-censored technique survival in patients treated with APD
vs those treated with CAPD, using data from the Australia and
New Zealand Dialysis and Transplant (ANZDATA) Registry.
RESULTS
Patient characteristics
In total, 4128 patients underwent PD over 6981 person-years.
Out of these, 1735 (42%) patients were treated with at
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least one episode of APD (Table 1). Of these 1735
patients, 498 (28.7%) started APD as the first PD modality.
The patients in the APD group spent 63.4% of the total
PD career duration on APD. The patients in the APD
group were more likely to be younger (55.8±17.3 vs
60±14.6 years, Po0.001), males (56.5 vs 50.7%,
Po0.001), and Caucasian (74.3 vs 67.7%, Po0.001). The
patients in the APD group were also less likely to have
comorbid conditions than that in the CAPD group, such
as coronary artery disease (33.8 vs 40.3%, Po0.001),
cerebrovascular disease (12.9 vs 15.1%, P¼ 0.048), and
diabetes mellitus (32.7 vs 40.6%, Po0.001). APD patients
had marginally lower body mass index (BMI) at initiation of
PD (25.6±5.2 vs 26.3±5.2 kg m2, Po0.001). Mean baseline
dialysate–plasma creatinine ratio at 4 h in the APD group was
slightly higher than that in the CAPD group (0.70±0.12 vs
0.69±0.12, P¼ 0.001).
Patient survival
The crude death rate varied over time (Table 2), but on
univariate analysis (see Table 3 and Figure 1), the mortality
rate during APD treatment was comparable to that during
CAPD treatment (unadjusted hazard ratio (UHR) 0.92, 95%
CI 0.77–1.09, P¼ 0.336).
On univariate Cox proportional hazard model analysis,
other factors that were associated with increased patient
mortality were older age, presence of comorbid conditions
(chronic lung disease, coronary artery disease, peripheral
vascular disease, cerebrovascular disease, and diabetes),
former smoking status, and high peritoneal membrane
transport status. Certain racial groups (Maori, Pacific
Islander, Cook Islander, Samoan, Tongan, and Asian) were
associated with lower patient mortality.
In the multivariate analysis, the patients had comparable
mortality during APD treatment compared to that during
Table 1 | Patient characteristics at commencement of PD (CAPD group, treated entirely with CAPD; APD group, with at least
one episode of APD)
Characteristic All patients CAPD group APD group
Number of patients 4128 2393 (58%) 1735 (42%)
Follow-up in person-years 6981 3819 3162
Malea 2192 (53%) 1212 (51%) 980 (56%)
Age (years)a 58.2±16.0 60.0±14.6 55.8±17.3
Racial origina
Caucasians 2895 (70%) 1619 (68%) 1276 (74%)
Aboriginal, Torres Strait
Islander
223 (5%) 127 (5%) 96 (6%)
Maori, Pacific Islander,
Cook Islander, Samoan,
Tongan
563 (14%) 385 (16%) 178 (10%)
Asian 380 (9%) 221 (9%) 159 (9%)
Others 67 (2%) 41 (2%) 26 (2%)
Chronic lung disease 536 (13%) 328 (14%) 208 (12%)
Coronary artery diseasea 1550 (38%) 964 (40%) 586 (34%)
Peripheral vascular disease 1037 (25%) 617 (26%) 420 (24%)
Cerebrovascular diseaseb 585 (14%) 361 (15%) 224 (13%)
Diabetes mellitusa 1540 (37%) 972 (41%) 568 (33%)
Smoking status
Never 2023 (49%) 1142 (48%) 881 (51%)
Former 1590 (39%) 939 (39%) 651 (38%)
Current 515 (12%) 312 (13%) 203 (12%)
Body mass index (kg m2)a 26.0±5.2 26.3±5.2 25.6±5.2
p19.9 409 (10%) 201 (8%) 208 (12%)
20–24.9 1511 (37%) 858 (36%) 653 (38%)
25–29.9 1373 (33%) 815 (34%) 558 (32%)
X30 832 (20%) 518 (22%) 314 (18%)
D–P Cr 4 hb 0.69±0.12 0.69±0.12 0.70±0.12
Peritoneal membrane transport statusb
Low 206 (5%) 124 (5%) 82 (5%)
Low average 1196 (29%) 732 (31%) 464 (27%)
High average 2053 (50%) 1174 (49%) 879 (51%)
High 673 (16%) 363 (15%) 310 (18%)
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; D–P Cr 4 h, dialysate–plasma creatinine ratio at 4 h; PD, peritoneal dialysis.
aPp0.001.
bPp0.05.
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CAPD treatment (adjusted hazard ratio (AHR) 1.03, 95% CI
0.86–1.24, P¼ 0.723). The factors independently associated
with mortality were older age, Aboriginal and Torres Trait
Islander racial origin, coronary artery disease, peripheral
vascular disease, cerebrovascular disease, and diabetes
mellitus. The patients of Asian racial origin had better
overall survival.
Of the 1735 patients treated with at least one episode of
APD, 434 (28.7%) were treated entirely with APD (never
CAPD). A subgroup analysis was performed to compare the
outcomes in the patients treated entirely with CAPD
(n¼ 2393) and those treated entirely with APD (n¼ 434).
When compared to CAPD, the patients treated entirely with
APD had a lower death rate on univariate analysis (UHR
0.74, 95% CI 0.57–0.96, P¼ 0.023) and a comparable death
rate on multivariate analysis after adjusting for the
confounding variables (AHR 0.89, 95% CI 0.67–1.20,
P¼ 0.454).
Death-censored technique failure
The crude death-censored technique failure rate varied over
time, but was similar between APD and CAPD (Table 4). On
univariate analysis (see Table 5 and Figure 2), the patients
had comparable death-censored technique failure during
APD treatment compared to that during CAPD treatment
(UHR 1.09, 95% CI 0.92–1.30, P¼ 0.32). Other factors that
were associated with higher death-censored technique failure
were Aboriginal and Torres Strait Islander racial origin,
obesity (BMI X30 kg m2), and high peritoneal membrane
transport status. Patients of Asian racial origin were
associated with lower death-censored technique failure.
Table 2 | Crude death rates and relative risk by PD modality
and at specified time intervals
Time
interval
Death rate per
100 person-years
Relative risk 95% CI
CAPD APD
0–1 6.3 7.8 1.23 0.86–1.73
1–2 14.7 11.9 0.81 0.61–1.07
2–3 18.7 19.4 1.03 0.77–1.39
43 23.8 21.1 0.89 0.68–1.16
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal
dialysis; CI, confidence interval; PD, peritoneal dialysis.
Table 3 | Risk of patient death by Cox proportional hazard model
Univariate analysis Multivariate analysis
Covariate UHR (95% CI) P-value AHR (95% CI) P-value
APD treatment 0.92 (0.77–1.09) 0.336 1.03 (0.86–1.24) 0.723
Female 0.90 (0.78–1.03) 0.131
Age (per year) 1.04 (1.03–1.05) o0.001 1.04 (1.03–1.05) o0.001
Racial origin
Caucasians Reference Reference
Aboriginal, Torres Strait Islander 1.30 (0.93–1.82) 0.131 1.80 (1.34–2.42) o0.001
Maori, Pacific Islander,
Cook Islander, Samoan, Tongan
0.86 (0.75–1.00) 0.048
Asian 0.67 (0.52–0.86) 0.002 0.73 (0.58–0.90) 0.004
Others 0.35 (0.15–0.84) 0.019
Chronic lung disease 1.60 (1.35–1.90) o0.001
Coronary artery disease 2.64 (2.19–3.18) o0.001 1.47 (1.22–1.77) o0.001
Peripheral vascular disease 2.46 (2.12–2.85) o0.001 1.44 (1.24–1.68) o0.001
Cerebrovascular disease 2.03 (1.67–2.48) o0.001 1.22 (1.01–1.49) 0.040
Diabetes mellitus 1.77 (1.56–2.02) o0.001 1.58 (1.35–1.84) o0.001
Smoking status
Never Reference
Former 1.34 (1.13–1.57) o0.001
Current 0.95 (0.77–1.17) 0.617
Body mass index (kg m2)
p19.9 0.79 (0.58–1.06) 0.112
20–24.9 Reference
25–29.9 1.02 (0.89–1.18) 0.737
X30 1.31 (0.93–1.48) 0.189
Peritoneal membrane transport status
Low 0.97 (0.67–1.42) 0.883
Low average Reference
High average 1.16 (0.96–1.39) 0.118
High 1.28 (1.06–1.55) 0.009
AHR, adjusted hazard ratio; APD, automated peritoneal dialysis; CI, confidence interval; UHR, unadjusted hazard ratio.
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On multivariate Cox proportional hazards model analyses,
no significant differences were observed in death-censored
technique survival between the APD and CAPD treatments
(AHR 1.08, 95% CI 0.91–1.27, P¼ 0.381). The factors
associated with more frequent technique failure were
Aboriginal and Torres Strait Islander racial origin, BMI more
than 25 kg m2, and high peritoneal membrane transport
status. The patients of Asian racial origin had better death-
censored technique survival. When death was accounted as a
cause of technique failure, it was comparable in both the
groups (Table 6) on univariate and multivariate Cox
proportional hazards model analyses.
The first-order interaction between the modality of PD
treatment with the time interval either before or after the
occurrence of the first technique failure was not significant
(hazard ratio (HR) 0.90, 95% CI 0.62–1.32, P¼ 0.603).
However, in all the 4128 patients, the risk of death-censored
technique failure for the subsequent time interval after the
first occurrence of failure was higher (HR 2.14, 95% CI
1.57–2.91, Po0.001). Death-censored technique survival was
inferior in both modalities of PD after the occurrence of the
first failure (with CAPD before the first failure as reference,
HR for CAPD, and APD after the first failure 2.14, 95% CI
1.57–2.91, Po0.001, and 2.13, 95% CI 1.62–2.81, Po0.001,
respectively) (Figure 3). In other words, patients who
experienced PD technique failure were more likely to
experience technique failure again if they subsequently
returned to PD, irrespective of whether they initially received
APD or CAPD.
Additional analyses were performed to evaluate both
death-censored and uncensored technique failures for the
first occurrence of failure. Both the failure rates were similar
in univariate and multivariate Cox proportional hazards
model analyses (Table 6). In another subgroup analysis, as
compared to the patients treated entirely with CAPD
(n¼ 2393), those treated entirely with APD (n¼ 434) had
comparable death-censored technique failure on both
univariate (UHR 1.10, 95% CI 0.90–1.35, P¼ 0.351)
and multivariate analyses (AHR 1.08, 95% CI 0.88–1.33,
P¼ 0.44).
Propensity score analysis
The logistic regression model (Table 7) using PD modality as
the dependent variable was used to calculate propensity score
(PS). The patients were divided into five quintiles of the PS
(data not shown). There were no significant differences in
mortality in the two groups of PD modality when PSs were
added to the final multivariate analysis (Table 8) as a
continuous variable (HR 0.84, 95% CI 0.68–1.03, P 0.09) as
well as a categorical variable of quintiles of the PS (HR 0.83,
95% CI 0.68–1.02, P 0.083). Death-censored technique
survival was comparable in the two groups when PSs were
added to the final multivariate analysis (Table 8) as a
continuous variable (AHR 1.07, 95% CI 0.91–1.27, P 0.381)
as well as a categorical variable of quintiles of the PS (AHR
1.07, 95% CI 0.91–1.26, P 0.413).
DISCUSSION
This large, registry study found that patient mortality and
technique failure were comparable between APD and CAPD.
Independent of PD modality, the first technique failure
increased the risk of death-censored technique failure in the
subsequent time interval. These conclusions were robust
across several approaches to analysis and persisted after
adjusting for discrepancies in baseline characteristics.
These findings differ to those of a retrospective, observa-
tional cohort study of 40 869 North American PD patients in
which APD was reported to be associated with lower risks of
both mortality and technique failure.28 The apparent
disparity in observations may have been partly due to the
fact that the North American study only included patients
using Baxter Healthcare PD systems, thereby introducing the
possibility of selection bias. Moreover, statistical adjustments
were made only for a limited number of variables (age,
diabetes mellitus, new to dialysis vs transfer from hemodialysis),
so residual confounding was possible.
In contrast, several other studies including ours have not
observed any significant differences in survival or technique
success between the PD modalities.9,21,27,29 Two randomized
controlled trials of APD vs CAPD treatment reported similar
death and technique failure rates,21,29 although the sample
sizes were small (82 and 34 subjects, respectively) and a type
2 statistical error could not be excluded. A prospective,
single-center study of 104 PD patients also found that PD
modality was not a significant, independent predictor of
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Figure 1 | Kaplan–Meier graph showing patient survival: patient
survival was comparable during CAPD and APD treatment
modalities.
Table 4 | Crude death-censored technique failure rates and
relative risk by PD modality and at specified time intervals
Failure rate per 100 person-years
Time interval CAPD APD Relative risk 95% CI
0–1 14.8 18.8 1.27 1.02–1.59
1–2 22.8 22.6 0.99 0.80–1.21
2–3 19.7 22.6 1.14 0.86–1.51
43 24.9 30.4 1.22 0.96–1.55
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal
dialysis; CI, confidence interval; PD, peritoneal dialysis.
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cardiovascular mortality.27 Similarly, Fine and Ho9 recently
reported comparable outcomes for APD and CAPD in 2420
pediatric patients registered on the North American Pediatric
Renal Transplant Cooperative Study (NPRTCS) database.
Technique failure was not significantly different between the
two groups, although APD was observed to be associated
with a longer time to first peritonitis episode. However, no
adjustments were made for the significant differences in
characteristics between children treated with the two PD
modalities.
This study was unable to compare peritonitis-free survival
between APD and CAPD regimens, because during the
period of the study the ANZDATA Registry only collected
information on the date of the first peritonitis episode in a
patient’s PD career and not thereafter, even if the PD sub-
modality changed. Previous studies have suggested that
peritonitis rates are lower on APD than on CAPD.4–9
However, these differences could potentially reflect patient
selection, particularly because not all studies have observed a
lower peritonitis occurrence in APD patients.19,20
In Australia and New Zealand, peritonitis is the major
cause of PD technique failure, accounting for up to 40% of
cases.2 Other common causes of technique failure, such as
ultrafiltration failure (9%) and inadequate small solute
clearance (12%), have also been purported to be favorably
modified by APD.10–12,16,17 There is some evidence to suggest
that, for most patients (except possibly low and low-average
transporters), better small solute clearances are achievable on
Table 5 | Risk of death-censored technique survival by Cox proportional hazard model
Univariate analysis Multivariate analysis
Covariate UHR (95% CI) P-value AHR (95% CI) P-value
APD treatment 1.09 (0.92–1.30) 0.319 1.08 (0.91–1.27) 0.381
Female 0.97 (0.86–1.09) 0.572
Age (per year) 1.00 (0.99–1.00) 0.823
Racial origin
Caucasians Reference Reference
Aboriginal, Torres Strait Islander 1.42 (1.18–1.70) o0.001 1.40 (1.15–1.70) 0.001
Maori, Pacific Islander, Cook Islander,
Samoan, Tongan
0.84 (0.61–1.17) 0.314
Asian 0.70 (0.56–0.87) 0.002 0.74 (0.59–0.92) 0.008
Others 0.73 (0.52–1.02) 0.063
Chronic lung disease 0.99 (0.85–1.14) 0.858
Coronary artery disease 0.99 (0.88–1.10) 0.796
Peripheral vascular disease 1.00 (0.90–1.11) 0.962
Cerebrovascular disease 0.88 (0.75–1.03) 0.115
Diabetes mellitus 0.98 (0.88–1.09) 0.720
Smoking status
Never Reference
Former 1.03 (0.93–1.14) 0.616
Current 0.98 (0.85–1.13) 0.825
Body mass index (kg m2)
p19.9 0.89 (0.73–1.09) 0.262
20–24.9 Reference Reference
25–29.9 1.10 (0.98–1.22) 0.109 1.11 (1.00–1.23) 0.05
X30 1.30 (1.11–1.52) 0.001 1.35 (1.16–1.58) o0.001
Peritoneal membrane transport status
Low 0.92 (0.72–1.17) 0.483
Low average Reference
High average 1.05 (0.91–1.22) 0.477
High 1.18 (1.01–1.38) 0.042 1.19 (1.02–1.40) 0.031
AHR, adjusted hazard ratio; APD, automated peritoneal dialysis; CI, confidence interval; UHR, unadjusted hazard ratio.
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Death-censored technique survival by PD modality
Figure 2 | Kaplan–Meier graph showing death-censored
technique survival: death-censored technique survival was
comparable during CAPD and APD treatment modalities.
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certain APD regimens compared with CAPD regimens.16,17
Rodriguez et al.25 demonstrated in their prospective sequen-
tial study that APD regimens resulted in significantly better
peritoneal Kt/V (up to 34%) and creatinine clearance (up to
24%) values than CAPD regimens, even in low transporters.
In practice though, APD patients appear to be less likely to
achieve their adequacy targets than CAPD patients.24,30
Similarly, studies have generally not shown an advantage of
APD over CAPD for peritoneal fluid removal,22,25 and some
have even observed worse peritoneal ultrafiltration and
sodium removal in APD-treated patients.23,27,31 The Inter-
national Society of Peritoneal Dialysis ad hoc Committee on
Ultrafiltration Management in Peritoneal Dialysis recom-
mends APD for ultrafiltration failure in patients with high
transport status.12 However, the only randomized controlled
trial of APD vs CAPD in high and high-average transporters
actually demonstrated lower (but not statistically significant)
net ultrafiltration volumes in patients treated with APD vs
CAPD (1092±442 vs 1190±343 ml day1, respectively).21
If APD did have any beneficial effects on peritonitis rates,
peritoneal small solute clearances, and fluid removal in our
study, they were not of sufficient magnitude to collectively
impact on patient survival or technique success. An
alternative possibility is that any propitious effects of APD
may have been counterbalanced by deleterious consequences.
For example, residual renal function has been shown to be
one of the strongest independent predictors of patient and
technique survival,32,33 and to be lost at a more rapid rate
with APD treatment compared with CAPD.22,26,27 Other
studies, however, have not found any influence of PD
modality on the decline of residual renal function.25,29,34–39
The strengths of this study lie in its large cohort size and
the rigor and robustness of the statistical analyses performed.
Thus, not only all the patients but also all the PD episodes
recorded in the Registry were included in the study. Time on
each modality was accounted for by including PD modality
as a time-dependent covariate. Moreover, as shown in other
studies,9,28 the APD and CAPD groups exhibited significant
differences with respect to a number of baseline character-
istics; hence, all of these characteristics were adjusted for in
the multivariate Cox proportional hazards models. In
addition, the PS approach was used to adjust for potential
confounders and selection bias. The PS method can be used
to confirm and support the results obtained from a well-
constructed Cox proportional hazard model.40,41
Nevertheless, the study had a number of limitations.
Analyses of the relationships of PD modality with the
different causes of technique failure (particularly peritonitis,
ultrafiltration failure, and inadequate small solute clearance)
were not possible because of the way in which ANZDATA
collects this information. The pattern and the effect of loss of
residual renal function in APD and CAPD patients on the
various outcomes also could not be studied. We could not
study the effect of the dialysis dose on the outcomes in CAPD
and APD patients. Finally, although we were able to adjust for
reported comorbidities on a categorical basis, ANZDATA
does not collect information about the severity of comorbid-
ities, and hence it is difficult to entirely exclude the possibility
of residual confounding.
In conclusion, this study demonstrated that, following
adjustment for differences in baseline characteristics, APD
treatment resulted in similar patient survival and technique
success rates compared to CAPD in 4128 Australian and New
Zealand PD patients followed over 6982 person-years. There
is currently no strong basis, except lifestyle considerations,
for favoring the selection of one PD modality over another.
MATERIALS AND METHODS
Study population
The study included all patients from the ANZDATA Registry who
started PD between 1 April 1999 and 31 March 2004.
The ANZDATA Registry collects information every 6 months
from all renal units throughout Australia and New Zealand on
voluntary basis, concerning all patients receiving chronic renal
Table 6 | Subgroup analyses of Cox proportional hazard models for technique failure
Univariate analysis Multivariate analysis
UHR 95% CI P-value AHR 95% CI P-value
Uncensored technique failure 1.02 0.89–1.17 0.751 1.07 0.94–1.21 0.304
Death-censored technique failure
for the 1st occurrence of failure
1.02 0.89–1.16 0.798 1.07 0.95–1.21 0.289
Uncensored technique failure for
the 1st occurrence of failure
1.10 0.93–1.31 0.261 1.09 0.93–1.27 0.310
AHR, Adjusted hazard ratio; CI, Confidence interval; UHR, Unadjusted hazard ratio.
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Figure 3 | Kaplan–Meier graph showing the effect of the first
technique failure on death-censored technique survival: death-
censored technique failure was inferior in both the types of PD
modality after the occurrence of the first failure.
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replacement therapy. Complete details of the structure and methods
of the ANZDATA Registry have been reported elsewhere.42 In
summary, the collection is complete from the first renal replacement
therapy procedure in Australasia in 1963 and includes all patients
from all renal units in both countries. The data collected consist of
information on the underlying cause of end-stage renal disease,
demographic details, a limited range of comorbidities (the presence
of coronary artery disease, peripheral vascular disease, cerebrovas-
cular disease, chronic lung disease, diabetes, hypertension, and
smoking), the type of each dialysis episode, details about kidney
transplantation, and from 1 April 1999 measurements of height and
dialysate–plasma creatinine ratio at 4 h. Peritoneal equilibration tests
were requested to be performed within 6 months of the
commencement of PD, and at least 4 weeks apart from any
peritonitis episodes after 1 April 1999.
For this study, APD was defined as the use of a cycler for PD
treatment, including nightly intermittent peritoneal dialysis, con-
tinuous cycling peritoneal dialysis, or tidal peritoneal dialysis
(nightly tidal PD or continuous tidal PD). BMI was calculated
from the quotient of the weight and the square of the height at the
commencement of renal replacement therapy and was analyzed as a
categorical variable. Peritoneal transport status was analyzed as a
categorical variable according to the four groupings of dialysate–-
plasma creatinine ratio at 4 h values defined by Twardowski et al.43
(low, o0.50; low-average, 0.50–0.64; high-average, 0.65–0.80; and
high, X0.81).
The outcomes examined were patient death and death-censored
technique failure. If a patient died within 60 days after transfer to
hemodialysis, then the death was attributed to PD, because such
early deaths were considered to reflect the health status of patients
Table 7 | Variables entered into the multiple logistic regression model to derive propensity scores for the likelihood of APD as
PD modality
Variable Odds ratio (95% CI) P-value
Female gender 0.81 0.73–0.89 o0.001
Age (years) 0.99 0.98–0.99 o0.001
Racial origin
Caucasians Reference
Aboriginal, Torres Strait Islander 0.97 0.79–1.19 0.754
Maori, Pacific Islander,
Cook Islander, Samoan, Tongan
0.57 0.49–0.67 o0.001
Asian 0.87 0.74–1.03 0.1
Others 0.72 0.49–1.05 0.091
Chronic lung disease 0.93 0.80–1.07 0.302
Coronary artery disease 0.93 0.83–1.04 0.223
Peripheral vascular disease 1.17 1.03–1.33 0.013
Cerebrovascular disease 0.98 0.85–1.13 0.751
Diabetes mellitus 0.82 0.74–0.91 o0.001
Smoking status
Never Reference
Former 0.91 0.82–1.00 0.062
Current 0.76 0.66–0.89 o0.001
Body mass index (kg m2)
p19.9 1.20 1.03–1.40 0.021
20–24.9 Reference
25–29.9 0.98 0.88–1.10 0.781
X30 0.96 0.84–1.09 0.534
Peritoneal membrane transport status
Low 0.99 0.79–1.23 0.918
Low average Reference
High average 1.09 0.98–1.21 0.112
High 1.16 1.01–1.34 0.033
APD, automated peritoneal dialysis; CI, confidence interval; PD, peritoneal dialysis.
Table 8 | Cox proportional hazard models for patient mortality and death-censored technique failure
Patient mortality Death-censored technique failure
Model HR 95% CI P-value HR 95% CI P-value
Unadjusted 0.92 0.77–1.09 0.336 1.09 0.92–1.30 0.319
Adjusted 1.03 0.86–1.24 0.723 1.08 0.91–1.27 0.381
Adjusted+PS 0.84 0.68–1.03 0.09 1.07 0.91–1.27 0.381
Adjusted+PS in quintiles 0.83 0.68–1.02 0.083 1.07 0.91–1.26 0.413
CI, confidence interval; HR, hazard ratio; PS, propensity score.
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during the period of failing PD therapy. In contrast, deaths that
occurred in less than 60 days after cessation of PD due to renal
transplantation were not attributed to PD, and such episodes were
censored at the end of PD treatment. Death-censored technique
failure was defined as a transfer from PD to hemodialysis for more
than 1 month and was examined without counting death during
treatment as a failure. Change of one PD modality to another was
not considered as a technique failure. For both of these outcomes,
survival time was calculated from the date of commencement of
each PD episode to the date of death, transfer to hemodialysis,
transplantation, loss of follow up, or 31 March 2004.
Statistical analysis
For the purpose of describing the population (as outlined above and
Table 1), the patients were divided into two groups, patients treated
entirely with CAPD (CAPD group) and patients having had at least
one APD episode (APD group). For the Registry, each episode is
defined as the period of minimum 1 month during which the
dialysis modality is unchanged. With every change in the dialysis
modality, a new episode begins and each episode is calculated
precisely from the start date to the end date. These episodes are
numbered in a chronological order as ‘sequence numbers.’ Results
were expressed as frequencies and percentages for categorical
variables, mean±s.d. for continuous variables, and median and
interquartile range for non-parametric data. Distributions of
categorical variables across the two groups were compared by
means of w2 test, continuous variables by t-test if parametric, and
Mann–Whitney test if non-parametric.
Analyses of patient mortality and death-censored technique
survival used time-to-event analysis techniques. Univariate descrip-
tions used Kaplan–Meier survival analyses. Multivariate Cox
proportional hazards models were created using backward stepwise
elimination process using likelihood ratio test if P40.05. PD
modality was included as a time-dependent covariate using the dates
of each individual PD episode recorded in the Registry. This allowed
every episode of PD for every patient to be included in the analysis.
The other covariates included in the Cox models were gender, age,
race, coronary artery disease, peripheral vascular disease, cerebro-
vascular disease, chronic lung disease, diabetes mellitus, smoking,
BMI, and peritoneal transport status. We used the conditional risk
set model to analyze multiple entry data for death-censored
technique failure (taking the time from the end point of previous
episode as the beginning of the next episode).44 Standard errors were
calculated using robust variance estimation for the correlated data,
clustered according to the center of initial treatment.45 Proportional
hazard assumptions were checked and scaled by Schoenfeld
residuals, examined by formal hypothesis test and graphically.
The PSs or probability of being treated with APD were calculated
by using multivariate logistic regression, with PD modality as a
dependent variable.46 The variables included in the multivariate
logistic regression were gender, age, race, coronary artery disease,
peripheral vascular disease, cerebrovascular disease, chronic lung
disease, diabetes mellitus, smoking, BMI, and peritoneal transport
status. The Pearson w2 goodness-of-fit statistic and Hosmer–Leme-
show goodness-of-fit test were used to validate the multivariate
logistic regression model. The patients were divided into five
quintiles of the PS. The patients in the first quintile had the lowest
probability of being treated with APD, whereas those in the fifth
quintile had the highest probability. The PS was entered in the
final Cox proportional hazard models as a continuous variable
as well as a categorical variable of quintiles. P-values less than 0.05
were considered statistically significant. Statistical analyses were
performed using Stata/SE 9.2 (College Station, TX, USA) statistical
software.
Additional analyses
A separate analysis was performed to evaluate the technique failure
without censoring for death, as it is possible that ineffectiveness of
PD could be contributing to death in certain patients. The first
occurrence of technique failure may increase the risk of subsequent
technique failures. Hence, additional analyses were performed to
evaluate the technique failure (both death-censored and non-
censored) for the first occurrence only.
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